Multiparametric Magnetic Resonance Imaging of the Prostate and Prostate-specific Membrane Positron Emission Tomography Prior to Prostate Biopsy (MP4 Study)

被引:4
|
作者
Woo, Henry H. [1 ,2 ,3 ]
Khanani, Hadia [2 ]
Thompson, Nadine J. [4 ]
Sorensen, Brian J. [4 ]
Baskaranathan, Sris [2 ,3 ]
Bergersen, Philip [2 ,3 ]
Chalasani, Venu [2 ,3 ]
Dean, Thomas [2 ,3 ]
Dias, Max [2 ,3 ]
Symons, James [1 ,2 ,3 ]
Wines, Michael [2 ,3 ]
Jain, Anika [2 ]
Nassour, Anthony -Joe [2 ]
Tarlinton, Lisa C. [2 ,4 ,5 ]
机构
[1] Australian Natl Univ, Coll Hlth & Med, Canberra, Australia
[2] Sydney Adventist Hosp, SAN Prostate Ctr Excellence, Sydney, NSW, Australia
[3] Sydney Adventist Hosp, Dept Urol, Sydney, NSW, Australia
[4] Sydney Adventist Hosp, SAN Radiol & Nucl Med, Sydney, NSW, Australia
[5] Sydney Adventist Hosp, SAN Radiol & Nucl Med, 185 Fox Rd, Wahroonga, NSW 2076, Australia
来源
关键词
Magnetic resonance imaging; Positron emission tomography; Prostate biopsy; Prostate cancer; Prostate -specific membrane; antigen; DIAGNOSTIC CERTAINTY; LEXICON;
D O I
10.1016/j.euros.2022.11.012
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Prostate-specific membrane antigen (PSMA) positron emission tomography/computerised tomography (PET/CT) is increasingly being utilised in the diagnostic pathway for prostate cancer (PCa). Recent publications have sug-gested that this might help identify those who can avoid biopsy.Objective: The primary objective of this study was to determine whether PET mag-netic resonance imaging (MRI) fusion could negate the need to biopsy prior to prostatectomy in a selected population of men.Design, setting, and participant: Multiparametric MRI (mpMRI) for PCa is our stan-dard of care prior to prostate biopsy. Biopsy-naive men with one or more Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesions >10 mm on mpMRI were invited to undergo PSMA PET/CT prior to biopsy. Following ethics approval, 60 men were recruited between September 2020 and March 2021. The key exclusion criteria included a previous history of PCa and previous prostate sur-gery or biopsy.Outcome measurements and statistical analysis: A positive PET MRI fusion scan was defined as "consistent with"as per the Memorial Sloan Kettering Cancer Center lexicon of certainty, and concordance with biopsy results was analysed. Clinically significant PCa (csPCa) was defined as grade group (GG) >= 2 on pathology. A chi-square analysis was performed with statistical significance defined at p < 0.05.Results and limitations: A total of 71 mpMRI lesions were positive on 61 (86%) PET MRI fusion scans. Fifty-nine of 61 lesions biopsied confirmed csPCa in 54 (92%). Of five of 59 lesions for which either biopsy was negative or low-grade cancer was found, three had rebiopsy of which two were confirmed to have csPCa corroborating with PET MRI fusion and one was reconfirmed to have GG1 only. For the remaining two, both had another lesion elsewhere in the gland confirming csPCa, and hence rebiopsy was not performed. Ultimately, 56 of 59 (95%) lesions with a positive PET MRI fusion scan were confirmed to have csPCa. All GG >3 can-cers had a positive PET MRI fusion scan. Conclusions: This prospective study of PET MRI fusion assessment of men with PI-RADS 4 or 5 lesion >10 mm on mpMRI confirms that the majority of men (95%) with a positive PET MRI fusion scan will have csPCa. This supports recently pub-lished retrospective data suggesting that selected men might avoid prostate biopsy prior to radical prostatectomy.Patient summary: In this research, we have confirmed that prostate-specific mem-brane antigen positron emission tomography/computerised tomography in combi-nation with magnetic resonance imaging could have an important role in enabling a diagnosis of prostate cancer. Using the combination of these scans, we could con-fidently predict the presence of aggressive prostate cancer in some men for which treatment is warranted. This means that there are some men who could possibility proceed directly to having prostate cancer surgery without the need for a confirma-tory prostate biopsy.(c) 2022 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creative-commons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:119 / 125
页数:7
相关论文
共 50 条
  • [31] Virtual Prostate Biopsy with Prostate-specific Membrane Antigen and Magnetic Resonance Imaging: Closer to Reality in a Subgroup of Prostate Cancer Patients?
    Pomykala, Kelsey L.
    Herrmann, Ken
    Emmett, Louise
    Lalumera, Elisabetta
    Fanti, Stefano
    EUROPEAN UROLOGY OPEN SCIENCE, 2022, 44 : 11 - 12
  • [32] Positron Emission Tomography-computed Tomography with Prostate-specific Membrane Antigen Ligands as a Promising Tool for Imaging of Prostate Cancer
    Haberkorn, Uwe
    Kopka, Klaus
    Hadaschik, Boris
    EUROPEAN UROLOGY, 2016, 69 (03) : 397 - 399
  • [33] Gleason Grade Group 4 prostate biopsy with no cancer seen on final pathology in the magnetic resonance imaging and Prostate Specific Membrane Antigen-Positron Emission Tomography era
    Mookerji, Nikhile
    Mittal, Rohan
    Hui, Amaris
    Pfanner, Tyler
    Broomfield, Stacey
    Dean, Luke
    Adam, Benjamin
    Fung, Christopher
    Tamm, Alexander
    Kinnaird, Adam
    IJU CASE REPORTS, 2023, 6 (06) : 337 - 340
  • [34] Case - Prostate-specific antigen bounce: A pitfall in prostate-specific membrane antigen positron emission tomography/computed tomography interpretation
    Pedro, Victor Polins
    Sistani, Golmehr
    Rachinsky, Irina
    Zukotynski, Katherine
    Bauman, Glenn
    Liu, Wei
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2021, 15 (11): : E620 - E621
  • [35] Better To Rule In or Rule Out Significant Prostate Cancer? The Added Value of Prostate-specific Membrane Antigen Positron Emission Tomography to Magnetic Resonance Imaging Diagnostic Pathways for Prostate Cancer
    Walz, Jochen
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (04): : 401 - 402
  • [36] Impact of a Novel Molecular Imaging Modality, Prostate-Specific Membrane Antigen Positron Emission Tomography, on the Management of Prostate Cancer
    Patel, Neal A.
    Reiter, Robert E.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (13) : 1497 - +
  • [37] Utility of prostate-specific antigen derivatives to minimize unnecessary magnetic resonance imaging in patients with prior negative prostate biopsy
    Song, S. H.
    Song, B.
    Hwang, S. I.
    Lee, H. J.
    Lee, H.
    Hong, S. K.
    Byun, S-s.
    Lee, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1533 - S1534
  • [38] Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen - Positron emission tomography and biopsy correlation
    Haseman, MK
    Reed, NL
    Rosental, SA
    CLINICAL NUCLEAR MEDICINE, 1996, 21 (09) : 704 - 713
  • [39] Detection and localisation of primary prostate cancer using 68gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology
    Kalapara, Arveen A.
    Nzenza, Tatenda
    Pan, Henry Y. C.
    Ballok, Zita
    Ramdave, Shakher
    O'Sullivan, Richard
    Ryan, Andrew
    Cherk, Martin
    Hofman, Michael S.
    Konety, Badrinath R.
    Lawrentschuk, Nathan
    Bolton, Damien
    Murphy, Declan G.
    Grummet, Jeremy P.
    Frydenberg, Mark
    BJU INTERNATIONAL, 2020, 126 (01) : 83 - 90
  • [40] Men's Acceptance of Screening for Prostate Cancer with Prostate-specific Antigen, Magnetic Resonance Imaging, and Prostate Biopsy
    Godtman, Rebecka Arnsrud
    Pettersson, Christina
    Svensson, Linda
    Kohestani, Kimia
    Bratt, Karin Stinesen
    Wallstrom, Jonas
    Mansson, Marianne
    Hellstrom, Mikael
    Hugosson, Jonas
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (03): : 553 - 562